Project Grant R03AI199793
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Tennessee Health Science Center a $468,368 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective May 1, 2026, through May 1, 2028. The award funds investigator-initiated biomedical research examining the role of leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4) in HIV-associated atherosclerosis. The research...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Tennessee Health Science Center a Project Grant totaling $163,852 under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of November 1, 2025, and completion date of April 14, 2027. The funded research, titled "Interrogation of SIDB-Dependent Septation for Echinocandin Potentiation in Invasive Aspergillosis Treatment,"...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $147,000 to the University of Montana on April 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This R03 Project Grant supports research investigating inter-strain recombinants of human cytomegalovirus (HCMV) as an in vitro model to better understand viral genetic diversity and phenotypic variation. The project addresses a critical research gap:...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Connecticut Health Center $263,375 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 20, 2026, with a completion date of March 31, 2028. This project grant funds research into the Herpes Simplex Virus (HSV) alkaline nuclease as a novel antiviral drug target. The research addresses the significant public health burden of genital herpes—a...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Utah $743,752 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a five-year investigator-initiated research project beginning August 1, 2025 and concluding July 31, 2030. This Project Grant supports fundamental biomedical research investigating the epigenetic mechanisms that govern CD4+ helper T cell dysfunction during chronic viral infections....
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $427,625 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Maryland, Baltimore, effective August 1, 2025, through July 31, 2027. This award funds basic biomedical research investigating CD27-mediated immune suppression mechanisms in hematopoietic stem and progenitor cells (HSPCs), innate immune cells, and non-hematopoietic cells. The...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Utah $423,500 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a two-year project period extending from July 1, 2025 through June 30, 2027. This R21 Project Grant supports the development and evaluation of a novel chimeric antigen receptor T regulatory cell (CAR TREG) therapeutic design that targets programmed death-1 (PD-1) to enhance...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Arkansas for Medical Sciences $420,335 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 23, 2025, for a project period extending through May 31, 2027. The project investigates the role of lytic viral genes in the pathogenesis of oncogenic gammaherpesviruses, specifically examining whether lytic gene expression drives the development and...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $847,000 in Project Grant funding to The University of Kentucky Research Foundation on July 15, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research, scheduled for completion by June 30, 2027, focuses on identifying the protective roles of CD180 and nucleotide oligomerization domain 1 (NOD1)—two pathogen-associated molecular pattern...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Tennessee Health Science Center $847,000 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 15, 2025, with a completion date of June 30, 2027. This Project Grant supports the development and evaluation of the ferret as a preclinical animal model for testing antiviral efficacy against Venezuelan Equine Encephalitis Virus (VEEV), a mosquito-borne...
Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Tennessee a $148,519 Project Grant (CFDA 93.855: Allergy and Infectious Diseases Research) effective June 24, 2026, with completion targeted for May 31, 2028. This R03 award funds the development of adipose-derived stem cells (ADSCs) as a novel, scalable, and physiologically relevant in vitro model system for studying Human Cytomegalovirus (HCMV) latency. The primary deliverables include establishing the conditions under which ADSCs support latent HCMV infection and generating comparative transcriptional analyses using RNA sequencing to evaluate the ADSC latency model against established latency models. The research addresses a critical gap in HCMV pathogenesis understanding by providing a more biologically relevant cellular system for investigating the mechanisms governing viral latency—a persistent challenge in developing effective antiviral therapies. Outcomes from this project are intended to advance the scientific foundation for future therapeutic development targeting viral reactivation prevention in immunocompromised individuals and developing fetuses. Work will be performed at the University of Tennessee's Knoxville campus.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $148.5k | 6/25/26 |